Gene expression profiling of DEHP-treated cardiomyocytes reveals potential causes of phthalate arrhythmogenicity

Nikki Gillum Posnack a, Norman H. Lee a, Ronald Brown b, Narine Sarvazyan a,∗

a The Pharmacology & Physiology Department, The George Washington University, 2300 Eye Street, Washington, DC 20037, United States
b Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD 20993, United States

ARTICLE INFO

Article history:
Received 16 July 2010
Received in revised form
14 September 2010
Accepted 15 September 2010
Available online 8 October 2010

Keywords:
Cardiac myocyte
Microarray
Gene expression
Phthalate
Connexin-43
Calcium handling
Arrhythmia

ABSTRACT

Background: Di-(2-ethylhexyl)-phthalate (DEHP) is a widely used plasticizer that imparts flexibility to polyvinyl chloride. We have recently reported that clinically relevant concentrations of DEHP can affect electrical coupling between cardiac myocytes causing significant rhythm disturbances. The underlying causes for this effect are currently unknown.

Objectives: To use data on global mRNA expression as a tool to reveal possible pathways leading to arrhythmogenic effects of DEHP.

Methods: Rat neonatal cardiomyocytes were treated with 50 µg/mL DEHP for 72 h. Extracted RNA samples were hybridized onto Affymetrix Rat Gene 1.0 ST arrays. The mRNA expression of a subset of genes was validated by qRT-PCR. In a second set of experiments, cells were treated in a concentration dependent manner to identify genes affected by low DEHP concentrations.

Results: DEHP exposure is associated with global changes in mRNA expression, with differentially expressed genes overrepresented in 47 Gene Ontology categories. Modified expression was detected for genes associated with cell electrical activity, calcium handling, adhesion and microtubular transport. For a number of key proteins, including kinesin, TGFβ2, α-tubulin, and α1 & β1 integrins, changes in mRNA levels were confirmed on the level of the protein expression. A number of genes associated with cell adhesion and electrical activity were identified as early DEHP targets as they were affected by concentrations as low as 1 µg/mL.

Conclusions: Exposure of neonatal rat cardiomyocytes to clinically relevant DEHP concentrations leads to global changes in mRNA expression. These changes help to explain the arrhythmogenic effects of phthalates on these cells.

© 2010 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Phthalates are used in a large variety of household and medical products as it allows stiff plastics, such as polyvinyl chloride, to become more flexible. Di-(2-ethylhexyl) phthalate (DEHP) is the most common phthalate used in PVC for medical devices and may represent up to 40% of the finished weight of the plastic. DEHP is highly hydrophobic, and as a result, it leaches from plastics following contact with blood, serum, and other lipophilic fluids (Jenke, 2006). Phthalate leaching is a source of concern for human health, particularly in neonatal intensive care units (Loff et al., 2000; Shea, 2003; Sjöberg et al., 1985). There are two main reasons for this concern. First, critically ill neonates undergo multiple medical interventions over a prolonged period of time and these procedures frequently employ the use of stored fluids for transfusion (nutritional, pharmacological, blood products) and flexible tubing. Multiple medical interventions can result in high DEHP exposure. It is estimated that neonatal intensive care patients can have a 26-fold higher phthalate exposure as compared to the average environmental exposure for children (Calafat et al., 2004). The second reason is a curtailed glucuronidation pathway, which is not fully established in young children. Because glucuronidation facilitates urinary excretion of phthalates, and other xenobiotics, underdevelopment of this pathway increases the duration of exposure due to slow excretion (Leeder and Kearns, 1997). Indeed, various regulatory agencies and advisory groups have expressed concern about the potential for DEHP to have adverse effects on neonates (Jahnke et al., 2005; Kavlock et al., 2002). There is a general awareness regarding the carcinogenic, reproductive and developmental

Abbreviations: DEHP, Di-(2-ethylhexyl) phthalate; TGF, Tumor growth factor; MEHP, Mono-(2-ethylhexyl) phthalate; DMSO, Dimethyl sulfoxide; MMP, Matrix metalloproteinase; DMEM, Dulbecco’s modified essential medium; FBS, Fetal Bovine Serum; PCA, Principle components analysis; qRT-PCR, Quantitative real-time RT-PCR; GO, Gene Ontology.

∗ Corresponding author. Tel.: +1 202 994 0626; fax: +1 202 994 3553. E-mail address: phynas@gmail.com (N. Sarvazyan).

0300–483X/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.tox.2010.09.007
effects of phthalates (FDA: Center for Devices and Radiological Health, 2002; Jahneke et al., 2005; Shea, 2003). In contrast, one rarely mentions the adverse effects of phthalates on the heart. Yet, negative inotropic or chronotropic effects have been observed following intravenous administration of DEHP or its primary metabolite, mono-(2-ethylhexyl) phthalate (MEHP), to experimental animals (Rock et al., 1987), isolated heart preparations (Peterse et al., 1975) and human myocardial tissue (Barry et al., 1990). DEHP perfusion of the isolated rat heart preparation resulted in electrophysiological changes as well, notably, prolongation of the PR and QT intervals (Aronson et al., 1985; Aronson et al., 1987). Our recent in vitro study in rat neonatal cardiomyocytes revealed the adverse effect of DEHP on conduction velocity, network synchronicity and monolayer mechanical motion (Gillum et al., 2009). Paradoxically, while DEHP decreased the amount of junctional connexin 43 protein, the levels of its mRNA were not affected. The data clearly pointed to multiple pathways that can be affected by DEHP exposure. The goal of this study was to determine whether DEHP induces global alterations in cardiomyocyte mRNA expression and, if so, whether these alterations can be linked to the observed changes in cell behavior. More specifically, we sought to identify molecular pathways affected by DEHP that might lead to cardiomyocyte electrical uncoupling and changes in monolayer motion and adhesion. To ensure future clinical relevance of our in vitro findings, DEHP was applied at doses and for durations that were comparable to neonatal exposure in a clinical setting (Karle et al., 1997; Loff et al., 2000; Sjoberg and Bondesson, 1985; Sjoberg et al., 1985).

2. Materials and methods

2.1. Chemicals

Collagenase II was obtained from Worthington (Freehold, NJ). Media and porcine trypsin were obtained from Gibco BRL (Grand Island, NY). Fluo-4, nuclear stain and Trizol were purchased from Invitrogen (Eugene, OR). Cy3-conjugated AffiNIPur fab fragment (donkey anti-goat or goat anti-mouse) and DyLight 488-conjugated AffiNIPur fab fragment (donkey anti-rabbit) were purchased from Jackson ImmunoResearch (West Grove, PA). Glyceraldehyde 3-phosphate dehydrogenase antibody was purchased from Millipore (Billerica, MA). Kinesin 20A, TGFβ2, α-actinin, and β-actinin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Affymetrix probe cDNA kit and SYBR green mastermix were purchased from Stratagene (La Jolla, CA). Connexin-43, α-tubulin, DEHP (Lot #112K3730) and all other chemicals were obtained from Sigma Chemical (St. Louis, MO) unless specified otherwise.

2.2. Cardiomyocyte culture

All experiments were performed according to the Institutional Animal Care and Use Committee of the George Washington University Medical Center, which follows Federal and State guidelines. Cardiomyocytes from 1- and 2-day-old Sprague–Dawley rats were obtained by a modified enzymatic digestion procedure (Arunyan et al., 2001). Hearts were removed and rinsed in a cold, calcium- and magnesium-free, Hank’s Buffered Salt Solution (CMF-HBSS), and then minced into ~1 mm³ pieces. Tissue pieces were incubated overnight at 4 °C in fresh CMF-HBSS containing 0.1 mg/ml trypsin. The next day, heart tissue was washed with fresh CMF-HBSS and treated with 0.4 mg/ml soybean trypsin inhibitor. The tissue was then collected in Leibovitz’s medium containing 0.8 mg/ml collagenase II and shaken for 30 min at 37 °C. The cells were then gently triturated, passed through a cell strainer to remove any undigested pieces, and centrifuged for 5 min at 17.5 × g. The pellet was resuspended in Dulbecco’s modified essential medium (DMEM) supplemented with 10% Fetal Bovine Serum and pre-plated for an hour to minimize the presence of fibroblasts, which attach more rapidly than myocytes. Unattached cells were then collected, counted and plated in a culture dish containing 25 mm laminin-coated glass coverslips (105 cells/cm²). Myocytes were then kept under standard culture conditions in DMEM, supplemented with 5% Fetal Bovine Serum, 10 U/ml penicillin and 1 µg/ml streptomycin.

2.3. Experimental protocol

On the third day after cell plating, cardiomyocytes formed an interconnected confluent network that exhibited rhythmic spontaneous contractions. A single dose of concentrated 50 mg/ml DEHP stock in DMSO was added directly to the cell media to achieve a final concentration of 50 µg/ml DEHP (Gillum et al., 2009). Cardiomyocytes were treated with DEHP for 72 h, before conducting all subsequent experiments, including: calcium transient recordings, microarray analysis, qRT-PCR, immunocytochemistry and western blot analysis. The final concentration of DMSO in DEHP-treated samples and the corresponding controls was 0.1%. Cardiomyocytes were visualized daily to monitor the appearance and beating behavior of the myocyte network. In a second set of experiments, cardiomyocytes were treated in a concentration-dependent manner (0, 1, 10 and 50 µg/ml DEHP) prior to microarray analysis, to determine whether mRNA expression is altered at lower concentrations.

2.4. Microarray sample preparation

Two sets of microarray experiments were performed, the first utilized 6 coverslips of cardiomyocytes for each treatment group (control, 50 µg/ml DEHP) and the second utilized 3 coverslips for each treatment group (0, 1, 10 and 50 µg/ml DEHP). Extensive analysis was conducted using the first set of microarray hybridizations, which enabled us to thoroughly examine the physiological effects previously reported at this concentration by our laboratory. To minimize variability, the same litter of pups was used to prepare cell monolayers for control and DEHP treated groups for each microarray experiment. RNA was isolated from cell preparations using Trizol, per the manufacturer’s instructions, and samples were treated with DNase. Samples were transferred to The Catherine Birch McCormick Center, where RNA integrity was validated and samples were processed for microarray chip hybridization.

2.5. Affymetrix gene arrays

To maximize our ability to reveal DEHP-specific changes each microarray experiment used the same litter of pups to compare control and DEHP-treated coverslips. Each coverslip was treated and processed independently. Microarray data processing, normalization (i.e., multi-array analysis [RMA]), statistical analyses and data visualization were accomplished using GeneSpring GX 10 software. Principle components analysis (PCA) demonstrated that the experimental groups of control and DEHP-treated samples were well separated by their mRNA expression profiles. Assigned groupings were also validated by examining inter-sample correlations, which demonstrated that replicates within an experimental group correlated best to other replicates within the same group. Hybridization spike-in control transcripts (i.e., BubB, BucC, BuxDx, CreX) were included in the hybridization experiments, which allow one to determine whether the in vitro transcription reaction, hybridization and washing steps were performed similarly across arrays. There were no significant differences in hybridization signal intensities for the controls, indicating that there were no methodological or quality control problems in the hybridization experiments.

Ingenuity pathway analysis is a bioinformatics resource that algorithmically identifies gene networks and canonical pathways based on millions of experimentally validated interactions between proteins, genes, complexes, cells, tissues, drugs, and diseases (www.ingenuity.com; Redwood, CA). A list of differentially expressed genes consisting of unique identifiers (e.g., RefSeq, GenBank accession, Affymetrix ID) and expression values was uploaded into the IPA knowledge database. To identify gene networks, IPA rank orders each gene in the list based on its interconnectedness with other genes (triangle connectivity). Next, the top interconnected genes (focus genes) are linked together as subnetworks based on specific connectivity (the extent that gene–gene connections overlap between top focus genes), and then combined with other subnetworks of focus genes with lower interconnectivity through the addition of linker genes (found either in the uploaded list or IPA’s Global Molecular Network) to produce a network.

2.6. Calcium transient recording

Cells were loaded with 5 µM Flu-4 and calcium transients were monitored at room temperature using a Zeiss LSM 510 confocal imaging system with standard 488 nm excitation/505–530 nm emission settings. Measurements were conducted in spontaneously beating cardiomyocyte cultures following 72 h treatment with either 50 µg/ml DEHP or 0.1% DMSO control.

2.7. Quantitative real-time RT-PCR

Quantitative real-time RT-PCR (qRT-PCR) validation of microarray results were performed on an ABI Prism 7700 Sequence Detection System, as previously described (Malek et al., 2002). Each RNA sample from cultured cardiomyocytes provided sufficient material (10–15 μg) for hybridization experiments and qRT-PCR validation assays. Total RNA was reverse transcribed using random primers as per the manufacturer’s protocol. The resulting cDNA was diluted and used as a template for qRT-PCR. Primers were selected for specificity by NCBI BLAST of the rat genome and amplicon specificity was verified by first derivative melting curve analysis using software provided by Perkin-Elmer/Applied Biosystems. Quantification and normalization of relative gene expression was accomplished using the comparative CT method or ΔΔCT. ΔΔCT values were converted into ratios by 2−ΔΔCT and averaged across biological replicates. The expression of the “housekeeping” gene glutamate dehydrogenase was used for normalization, as this gene typically does not exhibit differential expression in our microarray assays.
Fig. 1. Physiological changes in cardiomyocyte behavior caused by DEHP (50 μg/mL) treatment. (A) Calcium transient measurements were recorded from 4 regions of interest on a cardiomyocyte monolayer using Fluo-4, a calcium indicator dye. DEHP treatment (50 μg/mL) resulted in marked uncoupling between different regions of the cell network (right) compared with untreated control samples (left).

2.8. Immunocytochemistry

Cardiomyocytes were fixed using a standard 4% paraformaldehyde protocol, followed by staining with connexin-43 (1:500), kinesin 20a (1:50), α-tubulin (1:800), TGFβ2 (1:50), or nuclear stain (1:300). Samples were incubated with either Cy3-conjugated AffiniPur fab fragment (donkey anti-rabbit, donkey anti-goat) or donkey anti-rabbit Dylight 488-conjugated AffiniPur fab fragment (1:1000). Images were acquired and analyzed using a Zeiss LSM 510 confocal imaging system with dye-specific filter settings.

2.9. Western blot analysis

Cells were harvested in homogenization buffer containing 250 mM sucrose, 20 mM Heps, 1% sodium dodecyl sulfate, 1% Triton X-100, 2 mM dithiothreitol, 2 mM ethylenediaminetetraacetic acid, 2 mM ethylenebis(oxethylenedinitri)tetraacetic acid, 10 mM b-glycerophosphate, 1 mM orthovanadate, 2 mM phenylmethylsulfonyl fluoride, 20 μg/mL leupeptin, 10 μg/mL aprotinin, and 5 μg/mL pepstatin. Cells were incubated on ice in homogenization buffer for 15 min. Samples were sonicated three times for 15 s intervals on ice (Sonic Dismembrator, Fisher Scientific) and equal amounts of protein were loaded onto precise 4–20% gradient gels (Pierce). Blots were probed with α-integrin (1:500), β-integrin (1:500), α-tubulin (1:500), kinesin (1:200), TGFβ2 (1:200), and GAPDH (1:1000) for loading normalization. Blots were incubated with either goat anti-mouse, goat anti-rabbit or donkey anti-goat IgG AP conjugate (1:3000). Relative protein expression was assessed using a STORM 860 PhosphorImager.

3. Results

3.1. Physiological changes in DEHP-treated cardiomyocytes

We previously reported that delays in conduction velocity become more severe with increasing DEHP concentration and/or exposure time, which ultimately led to a loss of cardiac network synchronicity (Gillum et al., 2009). Fig. 1 illustrates the physiological effects of phthalate exposure upon treating confluent cardiomyocyte layers with 50 μg/mL DEHP for 72 h. In control samples, cardiomyocytes were beating synchronously and exhibited homogenous activation wavefronts with fast conduction velocity. In contrast, DEHP-treated myocytes showed marked uncoupling between different regions of the cell monolayer, leading to slow propagation of fractured wavefronts (Gillum et al., 2009). This effect was attributed to a smaller amount of punctuated connexin-43 staining in DEHP-treated samples. In addition, DEHP-treated samples exhibited an unusual "waterbed"-like pattern of motion (Gillum et al., 2009). The latter could not be explained by diminished electrical coupling, as pharmacological inhibition of gap junctions did not reproduce this effect. To reveal the multiple pathways that are affected by DEHP exposure we sought to comprehensively assess mRNA expression, as detailed below.

3.2. Genome-wide gene expression in DEHP treated samples

For the first set of experiments, six coverslips of cardiomyocytes were used for each treatment group (control, 50 μg/mL DEHP) to isolate total RNA and process for microarray chip hybridization. Array data were imported into GeneSpring GX 10 and principle components analysis demonstrated that the two experimental groups of control (red spheres) and DEHP samples (blue spheres) were well separated by their mRNA expression profiles (Fig. 2A). Assigned groupings were also validated by examining inter-sample correlations, which demonstrated that replicates within an experimental group correlated best to other replicates within the same group (Fig. 2B). A t-test with 10% false discover rate to correct for multiple testing (Benjamini and Hochberg, 1995) was then employed to identify statistically significant gene expression differences between control and 50 μg/mL DEHP-treated cardiomyocytes. At a 1.5-fold expression difference cut-off, a total of 845 mRNAs were differentially expressed. Of these 845 differentially expressed mRNAs, 362 were up-regulated and 483 were down-regulated by DEHP treatment (Fig. 2C). The expression differences (up or down) ranged from 1.5 to 11-fold. Gene Ontology (GO) analysis revealed that differentially expressed genes were significantly over-represented in 47 GO categories of which four are shown (p < 0.05 after adjustment for multiple testing). Categories of relevance to physiological changes observed after DEHP treatment of cardiac myocytes included: focal adhesion (GO:0005925, GO:0008357), myofibril (GO:0030016), ion binding (GO:0043167) and cytoskeletal (GO:0005856) (Fig. 2D–G).

3.3. Microarray validation

Differential expression of a subset of relevant genes was validated using qRT-PCR (Fig. 3). PCR primers were selected for specificity by NCBI BLAST of the rat genome and amplicon specificity was verified by first derivative melting curve analysis using software provided by Perkin-Elmer/Applied Biosystems. Data obtained from qRT-PCR analysis strongly correlated with that of microarray data (Fig. 3). Validated genes included those related to calcium handling (ryanodine receptor, calsequestrin, calponin, cardiac myosin), ion channels (sodium voltage-gated channels, potassium rectifier channels), cell adhesion (tensin, vinculin, plakophilin, integrin) and genes linked to connexin-43 expression and/or transport (tubulin, kinesin, TGFβ2).

### Diagram

![Diagram](https://via.placeholder.com/150)
Fig. 2. Microarray profiling of control and DEHP-treated (50 µg/mL) cardiomyocytes using gene and theme-based approaches. (A) Principle components analysis shows that the two treatment groups (control, DEHP) have different mRNA expression profiles. Control samples are shown as red dots and samples corresponding to cardiomyocytes treated with 50 µg/ml DEHP are shown in blue. (B) Assigned groupings were also validated by examining inter-sample correlations, which demonstrated that replicates within an experimental group correlated best to other replicates within the same group. (C) A t-test with 10% false discover rate (FDR) to correct for multiple testing was employed to identify statistically significant gene expression differences between control and DEHP-treated cardiomyocytes. At a 1.5-fold expression difference cut-off, a total of 845 mRNAs were differentially expressed. Of these 845 differentially expressed mRNAs, 362 were up-regulated and 483 were down-regulated by DEHP treatment. Gene Ontology (GO) analysis revealed that differentially expressed genes were significantly over-represented in 47 GO categories of which 4 are shown, including: focal adhesion (D), myofibril (E), ion binding (F), and cytoskeletal (G). Examples of key genes of interest are noted to the right of each GO category (p < 0.05 after adjustment for multiple testing).

3.4. Western blot and immunocytochemistry validation

For most relevant targets we used alternative means of validation to determine whether changes in mRNA expression correlated with modifications in protein expression and/or localization. Differential mRNA expression of tubulin and kinesin genes correlated with a reduction in protein expression (Fig. 4A and B). This down-regulation may translate to a decrease in microtubule formation...
3.5. Gene network analysis

To identify gene networks associated with DEHP treatment, differentially expressed genes identified in Fig. 2 were imported into Ingenuity Pathway Analysis (IPA) for network analysis. IPA represents a higher order analysis strategy that can be employed to identify biological themes associated with gene expression information (Hu et al., 2009). A number of gene networks relevant to myocardial function were identified. The latter included differentially expressed mRNAs associated with cardiac electrical disturbances, including arrhythmia and tachycardia (Fig. 5A). The affected genes included voltage-gated Na⁺ channels and potassium inward-rectifying channels (Fig. 5B). Additional studies will be required to confirm if changes in mRNA expression correlate with modifications in protein expression, localization and/or channel activity.

3.6. Modification of calcium handling

A comparison between the morphology of calcium transients in control and 50 μg/mL DEHP-treated samples revealed a significant prolongation in transient duration and an increase in the incidence of spontaneous double beats (Fig. 6A). The latter can lead to triggered activity, pointing to the potential arrhythmogenicity of phthalates via their adverse effects on calcium handling. Indeed, microarray analysis revealed significant changes in a number of key calcium handling proteins (Fig. 6B and C). DEHP-treated samples displayed diminished gene expression for calponin, troponin C and calsequestrin 2 (Fig. 6B and C). Conversely, DEHP-treatment enhanced the expression of other key calcium handling genes, including: ryanodine receptor 2, cardiac calcium transporting ATPase, triadin, voltage-dependent L-type calcium channel, phospholamban, sodium/potassium transporting ATPase and cardiac myosin heavy chain 6 (Fig. 6B and C).

3.7. Modified cell layer motion

In addition to electrical disturbances, DEHP treatment led to an unusual pattern of monolayer contractile motion [nicknamed “waterbed” effect due to its visual appearance] (Gillum et al., 2009). This observation suggested a decrease in cell attachment to the underlying surface, although the molecular mechanisms behind this effect are currently unknown. We previously showed that DEHP diminishes the expression of triton-insoluble vimentin protein, which constitutes fibroblast intermediate filaments. Indeed, microarray analysis revealed changes in vimentin gene expression (Fig. 7A). A second explanation for the observed changes in contractile monolayer motion is enhanced endothelin receptor (EDNRA, EDNRB) expression in DEHP-treated samples (Fig. 7B). Indeed, both matrix metalloproteinase 2 and 9 (MMP2, MMP9) were upregulated in DEHP-treated cardiomyocytes (Fig. 7B).
3.8. Concentration-dependent responses

A second set of microarray experiments were conducted to determine whether DEHP induces changes in mRNA expression at concentrations lower than 50 µg/mL. In these experiments, three coverslips of cardiomyocytes were used per treatment group (0, 1, 10 and 50 µg/mL DEHP). Differential mRNA expression was observed in all gene families of interest, including those related to calcium handling, protein trafficking, cell motility and arrhythmogenesis. Many of these genes were altered at 10 µg/mL DEHP dose, however a few were altered at concentrations as low as 1 µg/mL. These included vimentin (Fig. 7A), potassium ion channels (Fig. 7C),
and genes involved in mechanical adhesion junctions (Fig. 7D). One can suggest using these genes as early indicators of DEHP effects on cardiac tissue.

4. Discussion

DEHP is found in a variety of medical products, including: bags and tubing for the administration of blood, plasma, intravenous fluids, and total parenteral nutrition; nasogastric and enteral feeding tubes, umbilical catheters, and tubing used in hemodialysis, cardiopulmonary bypass, and extracorporeal membrane oxygenation (ECMO) blood circuits. Since DEHP is lipophilic, it will readily partition from the PVC in medical devices into whole blood, plasma, platelet concentrate, lipid-containing fluids (such as IV lipid emulsion), total parenteral nutrition solution, and solutions containing Polysorbate 80 and other formulation aids used to solubilize many intravenous medications (Jenke, 2006). Therefore, DEHP exposure increases dramatically with multiple medical interventions and whole blood products can reach as high as 620 µg/mL DEHP concentration (FDA: Center for Devices and Radiological Health, 2002). Notably, in our studies DEHP was applied at doses and for durations that were comparable to neonatal exposure in a clinical setting (Karle et al., 1997; Loff et al., 2000; Sjoberg and Bondesson, 1985; Sjoberg et al., 1985).

The main focus of this paper was to demonstrate that DEHP exposure causes differential expression of genes that can be associated with cardiac arrhythmias. Yet, many other pathways are also differentially expressed in response to DEHP. Affected GO categories included cholesterol & sterol biosynthetic and metabolic processes, which is in perfect agreement with numerous reports about endocrine effects of DEHP in a variety of cells and tissues (Kavlock et al., 2002). The cell cycle and regulation of cell growth
Fig. 6. Modifications in gene expression explain calcium handling dynamics in DEHP-treated cardiomyocytes. (A) Control and DEHP-treated (50 µg/mL) cardiomyocytes were loaded with Fluo-4 to analyze calcium transient morphology. DEHP-treated samples showed a significant increase in calcium transient upstroke duration compared to control (left). In addition, a large number of traces show evidence of double transients, indicating increased arrhythmogenicity (center). Individual calcium transients recorded from control and DEHP-treated cardiomyocytes are shown on the right. (B) Numerous calcium handling genes were shown to be differentially expressed in DEHP-treated samples (50 µg/mL) versus control. Calponin (CNN1), troponin C (TNNC1), calsequestrin 2 (CASQ2) and myosin light chain (MYL2) expression were decreased following DEHP treatment. Ryanodine receptor 2 (RYR2), cardiac calcium transporting ATPase (ATP2A2), triadin (TRDN), voltage-dependent L-type calcium channel (CACNA1C), phospholamban (PLN), and sodium/potassium transporting ATPase β2 (ATP1B2) were increased following DEHP treatment. (C) Cartoon illustrating key players involved in calcium handling within cardiomyocytes, which are modified following DEHP exposure.
were also on the list of significantly affected GO categories. Cardiac myocytes are terminally differentiated cells and as of today there are no published data linking DEHP and myocardial hypertrophy. Yet, the above mentioned data suggests that such a link could be further explored. Other major class of affected GO categories pointed to genes governing focal and cell-substrate adhesion, actin filaments and stress fibers (stress fibers connect to the sites where cell anchoring occurs, i.e., focal adhesions). This finding is in good agreement with our previous observations that monolayers of DEHP-treated myocytes exhibit dramatically different patterns of contractile motion (Gillum et al., 2009). Our future studies will systematically compare DEHP affected GO categories including PCR & western blot based validation of altered protein expression together with parallel measurements of associated phenotypical changes.

4.1. Connexin-43 trafficking & localization

Microarray data confirmed our previous PCR findings that DEHP treatment does not diminish the level of connexin-43 mRNA, despite the dramatic decrease in gap-junctional connexin-43 protein (Gillum et al., 2009). Connexin-43 is a very dynamic protein that requires assembly, trafficking to the cell membrane, stabilization and eventually turnover; the average lifespan of connexin-43 protein is a mere 1.5 h (Lauf et al., 2002). DEHP exposure produced changes in a number of tubulin (TUBB2B, TUBB2C, TUBB3, TUBA1A, TUBA1B, TUBA1C, TUBA4A) and kinesin genes (KIF2C, KIF4, KIF5C, KIF11, KIF18A, KIF20A). A decrease in the mRNA expression of these genes may explain the diminished gap junctional connexin-43 protein expression. Gap junction hemichannels migrate to the cell membrane via microtubules, which have insertion sites along the cell surface (Lauf et al., 2002). Heterodimerized alpha- and beta-tubulins form the major component of microtubules. Kinesins are motor proteins that move along microtubules carrying protein cargo toward the plasma membrane (Hirokawa and Noda, 2008; Shaw et al., 2007). Of the differentially expressed mRNAs, all tubulin and kinesins were downregulated in DEHP-treated samples. Indeed, the disruption of microtubules has been shown to reduce connexin-43 incorporation into gap junctions (George et al., 1999), and phthalate exposure has been shown to alter the organization of microtubules (Nakagomi et al., 2001). This observation offers the most plausible explanation for the reduced amount of functional connexin-43 protein we observed in DEHP-treated cardiomyocytes (Gillum et al., 2009). The second mechanism which may explain the observed decrease in gap-junctional connexin-43 protein is a reduction in growth factor secretion. Cardiomyocytes have been shown to release angiotensin II (Tamura et al., 1998), endothelin-1 (Yamazaki et al., 1996), vascular endothelial growth factor (Li et al., 1997) and transforming growth factor-β (Villarreal and Dillmann, 1992). Subsequent upregulation of
connexin-43 expression and an increase in conduction velocity has been attributed to secretion of these growth factors (Zhuang et al., 2000). Microarray data analysis of DEHP-treated samples revealed modifications in the mRNA expression of angiostatinogen (AGT), transforming growth factor-beta (TGFβ1, TGFβ2, TGFβ3), vascular endothelial growth factor (VEGF), and endothelin-1 (END1) (Figs. 2–4 and 7). Therefore, DEHP-induced alterations in growth factor secretion can be an additional factor that influences connexin-43 translation and/or stability in phthalate-treated samples.

### 4.2. Cardiomyocyte layer motion

Analysis of microarray data suggested possible mechanisms that may explain the effect on monolayer contractile motion caused by DEHP treatment. These include modifications in focal adhesion complexes, endothelin receptors, matrix metalloproteinase (MMP) and vimentin gene expression. Upregulation of endothelin receptors results in remodeling of MMPs and downregulation of connexin-43 through a common pathway (Peng et al., 2010). These MMPs are termed “gelatinases” and are known to degrade base-ment membrane proteins (Ahmed et al., 2006; Malla et al., 2008). An upregulation in MMP mRNA expression was observed following treatment with DEHP. Such degradation can lead to the “waterbed”-like irregular monolayer motion described previously (Gillum et al., 2009). Interestingly, an enhanced expression of MMP in Sertoli cells was reported after cell exposure to mono-ethylhexyl phthalate (MEHP), the primary metabolite of DEHP (Yao et al., 2010).

Our previous studies indicated diminished expression of triton-insoluble vimentin protein expression following DEHP-treatment of cardiomyocyte layers. Vimentin constitutes an essential part of fibroblast intermediate filaments (Wang and Stamenovic, 2002). We hypothesized that DEHP effects vimentin expression, which impacts the stiffness of the cardiac fibroblast layer found beneath cardiomyocytes in primary cultures. Indeed, microarray analysis revealed changes in vimentin gene expression in a concentration-dependent manner beginning at 1 μg/mL DEHP.

### 4.3. Calcium handling & arrhythmogenesis

Microarray analysis revealed that DEHP exposure alters the expression of key genes associated with ion channel and calcium handling proteins. This provides an explanation for DEHP-induced changes in calcium transient morphology and the occurrence of multiple double transients observed in DEHP samples. The latter can lead to triggered activity (Gyorke and Terentyev, 2008; Katra et al., 2007), pointing to the potential arrhythmogenicity of phthalates via their adverse effects on calcium handling. DEHP-treated samples displayed diminished gene expression for calponin, troponin-C and calsequestrin 2. Downregulation of the calcium binding proteins, calsequestrin and calponin, has been shown to trigger arrhythmia via calcium leak (Chopra et al., 2007; Gyorke et al., 2004). Interestingly, Park and Kwak (2009) observed a decrease in calponin gene expression in the insect Chironomus riparius, beginning as early as 1 h after DEHP exposure.

DEHP-treatment enhanced the expression of other key calcium handling genes, including: ryanodine receptor 2, cardiac calcium transporting ATPase, triadin, voltage-dependent L-type calcium channel, phospholamban, sodium/potassium transporting ATPase and myosin heavy chain 6. An influx of calcium through the L-type calcium channel serves as a trigger for calcium-induced calcium release via the ryanodine receptor (Fabiató and Fabiató, 1979; Nabauer et al., 1989) Calcium reuptake kinetics has been shown to influence triggered activity and spontaneous calcium release via the ryanodine receptor (Katá et al., 2007). Overexpression of triadin has been shown to predispose cardiac myocytes to arrhythmia, via its interaction with the ryanodine receptor (Terentev et al., 2005).

Lastly, our studies identified several groups, including members of the potassium channel and mechanical adhesion families, which are significantly affected by DEHP concentrations as low as 1 μg/mL (Fig. 7). PCR assessment of these genes may help to gauge early effects of DEHP on the cardiac function of most susceptible patients.

### 5. Conclusion

By assessing global changes in gene expression, we were able to identify several pathways that can be responsible for adverse effect of phthalates on cardiac muscle cells. Our analysis of altered gene expression was based on in vitro exposure of isolated rat cardiac muscle cells to DEHP. Additional steps will be necessary to establish the risk of DEHP-containing tubing in clinical settings. These steps include in vivo DEHP treatment of animals using clinically relevant routes of DEHP exposure, followed by electro- and echocardiographic measurements of cardiac function and validation of these conclusions in human subjects.

### Conflict of interest

None.

### Acknowledgements

The authors thank Luther Swift for isolation of cardiomyocytes and Yi Lian and Dr. Sydney Fu for their assistance with microarray processing. This work was supported by the National Institutes of Health (HL076722 to NS, 1F32ES019057 to NG and CA120316 to NHL) and the GWU Catherine Birch McCormick Center.

### References


